Controversy Over Adjuvant CDK4/6 Inhibitors in HER2-Negative Breast Cancer

4 Views

  • Thanks! Share it with your friends!

    You disliked this video. Thanks for the feedback!

admin
Published
In this video, John M. Burke, MD, Rocky Mountain Cancer Centers Associate Chair US Oncology Hematology Research Program in Aurora, Colorado, discusses the controversy surrounding the use of adjuvant CDK4/6 inhibitors ribociclib [Kisqali] and abemaciclib [Verzenio] for the treatment of HER2-negative breast cancer. Burke highlights 2 published articles that address design flaws in the phase 3 monarchE [NCT03155997] and phase 3 NATALEE [NCT03701334] trials, as well as the high costs associated with these treatments despite the uncertainty of achieving effective results.

For more resources and information regarding anticancer targeted therapies: http://targetedonc.com/
Category
Oncology
Be the first to comment

Up Next